Skip to Content

'
Stephen G. Swisher, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Robert F. Fly Professorship of Surgical Oncology, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Stephen Swisher is Professor and Chair of the Department of Thoracic and Cardiovascular Surgery.  Internationally recognized for his contributions to the staging and treatment of esophageal cancer and innovative translational research, Dr. Swisher devotes his efforts to clinical practice and research.

Born in Brooklyn, New York, Dr. Swisher received a bachelor’s degree in history and biology from Stanford University in 1982 and a medical degree with honors from the University of California at San Diego Medical School in 1986.  He interned and completed a general surgical residency at the University of California at Los Angeles, where he received the Golden Scalpel Chief Award.  In 1994, he became a cardiothoracic surgery fellow at St. Luke’s Episcopal Health System and The University of Texas M. D. Anderson Cancer Center, both in Houston.  

Dr. Swisher joined the faculty at M. D. Anderson Cancer Center in 1995 as junior faculty associate in the Department of Thoracic and Cardiovascular Surgery.  A year later, he was promoted to Assistant Professor of Surgery.  He was promoted to Associate Professor in 2001, Professor in 2005, and Department Chair in 2007.

Research Interests

Dr. Swisher’s research interests focus on the development of novel gene therapy strategies to treat esophageal and lung cancer patients.  His laboratory has documented the critical role of the double-stranded RNA protein kinase (PKR) in radiation resistance.  Efforts to overcome PKR radiation resistance have led to the development of a gene therapy vector which blocks PKR activity.  In collaboration with colleagues, he has also identified a novel gene that is down-regulated in lung tumors and KLF4.

Clinical Interests

Dr. Swisher’s clinical practice involves complex lung and esophageal cancer cases.  As a clinician investigator, he focuses on integrating multimodality approaches in esophageal cancer and evaluating novel gene therapy strategies in the clinic.  Enrolling patients in clinical trials is a top priority for him, and his participation in multidisciplinary conferences helps advance this program. 

Education & Training

Degree-Granting Education

1986 University of California at San Diego School of Medicine, San Diego, CA, MD, Medicine
1982 Stanford University, Stanford, CA, BA, History & Biology

Postgraduate Training

1994-1996 Fellow, Cardiothoracic Surgery, The University of Texas M. D. Anderson Cancer Center and St. Lukes Episcopal Hospital/Texas Heart Institute, Houston, TX
1991 Registrar, General Surgery, Nottingham University Hospital, Nottingham, United Kingdom
1990-1993 Resident, General Surgery, University of California at Los Angeles Medical Center, Los Angeles, CA
1988-1990 Fellow, Surgical Oncology, University of California at Los Angeles Medical Center, Los Angeles, CA
1987-1988 Resident, University of California at Los Angeles Medical Center, Los Angeles, CA
1986-1987 Intern, General Surgery, University of California at Los Angeles Medical Center, Los Angeles, CA

Board Certifications

1997 American Board of Thoracic Surgery
1994 American Board of Surgery
1987 National Board of Medical Examiners

Honors and Awards

2009 America's Top Doctors, Castle Connolly
2009 America's Top Surgeons, Consumers Research Council of America
2007-2009 America's Top Doctor for Cancer, Castle Connolly Medical Ltd.
2002-2006 The Surgery Chief Resident Surgical Training Award to the Thoracic Surgery Department at M.D. Anderson, University of Texas - Houston Medical School
2002 Resident Clinical Teaching Award, University of Texas
2000 Burroughs Wellcome Clinical Scientist Award in Translational Research, MDACC nominee
1993 Golden Scalpel Chief Award, UCLA Medical Center Resident
1986 Lange Publications Award, UCSD Medical School
1986 Surgery Honors, UCSD Medical School
1982 Phi Beta Kappa, Stanford University

Professional Memberships

American Association for Cancer Research, Philadelphia, PA
Member, 2000-present
American Association for Thoracic Surgery, Beverly, MA
Member, 2007-present
American Board of Thoracic Surgery, Chicago, IL
Member, 1997-present
American College of Surgeons, Chicago, IL
Fellow, 2000-present
American College of Surgeons Oncology Group, Durham, NC
Member, 2003-present
American Radium Society, Los Angeles, CA
Member, 2002-present
American Society of Clinical Oncology, Alexandria, VA
Member, 1997-present
American Society of Gastrointestinal Oncology, Melville, NY
Member, 2003-present
American Surgical Association, Beverly, MA
Member, 2007-present
Cooley Hands, TX
Member, 1996-present
Denton A. Cooley Cardiovascular Society, TX
Member, 1996-present
General Thoracic Surgical Club, Rochester, MN
Member, 2001-present
Harris County Medical Society, TX
Member, 1994-present
International Association for the Study of Lung Cancer, Aurora, CA
Fellowship Application Review Committee, 11/2007-11/2009
Member, 1996-present
International Society for Diseases of the Esophagus, Los Angeles, CA
Member, 1997-present
International Society of Gastrointestinal Cancer, Melville, NY
Member, 2003-present
Longmire Surgical Society, Los Angeles, CA
Member, 1993-present
Phi Beta Kappa Honor Society, San Diego, CA
Member, 1982-present
Society of Surgical Oncology, Arlington Heights, IL
Member, 2007-present
Society of Thoracic Surgeons, Chicago, IL
Member, 2005-present
Society of University Surgeons, Maitland, FL
Member, 2003-present
Southern Thoracic Surgical Association, Chicago, IL
Member, 2000-present
Texas Medical Association, TX
Member, 1994-present
University of Texas M. D. Anderson Associates, TX
Member, 1997-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Bolton WD, Rice DC, Correa AM, Hofstetter W, Komaki R, Mehran R, Pisters K, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Influence of Age on Choice of Therapy and Surgical Outcomes in Patients with Non-Small Cell Lung Cancer. Am Surg 75(7):598-603, 7/2009. PMID: 19655604.
2. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74(2):482-9, 6/1/2009. e-Pub 3/14/2009. PMID: 19289262.
3. Bolton WD, Rice DC, Coodyear A, Correa AM, Erasmus J, Hofstetter W, Komaki R, Mehran R, Pisters K, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Weaver J, Rhines L. Superior sulcus tumors with vertebral body involvement: A multimodality approach. J Thorac Cardiovasc Surg 137(6):1379-1387, 6/2009. PMID: 19464452.
4. Luthra R, Maru DM, Singh RR, Albarracin D, Yong L, Abraham R, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A. MicroRNA-196a is a Potential Marker of Progression During Barrett's Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus. Am J Pathol 174(5):1940-1948, 5/2009. e-Pub 3/2009. PMID: 19342367.
5. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-85, 4/1/2009. e-Pub 1/20/2009. PMID: 19156915.
6. Daliani DD, Tannis NM, Papandreou CN, Wang X, Swisher SG, Wood C, Swanson D, Logothetis CJ, Jonasch E. Prospective Assessment of Systemic Therapy Followed by Surgical Removal of Metastases in Selected Patients with Renal Cell Carcinoma. BJU Int. e-Pub 3/30/2009. PMID: 19338544.
7. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani J, Francis A, Maru D, Mehran RJ, Rice D, Roth JA, Walsh G, Vaporicyan AA. Esophageal Tumor Length is Independently Associated with Long-Term Survival. Cancer 115(3):508-516, 2/1/2009. PMID: 19117343.
8. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115(3):624-30, 2/1/2009. PMID: 19130466.
9. Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 16(4). e-Pub 2/5/2009. PMID: 19194759.
10. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-252, 2/2009. e-Pub 3/2009. PMID: 19106640.
11. Cen P, Correa AM, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus 22(1):32-41, 2009. e-Pub 11/19/2008. PMID: 19021684.
12. Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Swisher SG, Watson TJ, Blackstone EH. Worldwide esophageal cancer collaboration. Dis Esophagus 22(1):1-8, 2009. PMID: 19196264.
13. Hu W, Hofstetter WL, Wei X, Guo W, Zhou Y, Pataer A, Li H, Fang B, Swisher SG. Double-Stranded RNA-Dependent Protein Kinase (PKR)-Dependent Apoptosis Induction by a Novel Small Compound. J Pharmacol Exp Ther 328(3). e-Pub 12/9/2008. PMCID: PMC2658620.
14. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Yang G. Esophageal cancer. J Natl Compr Canc Netw 6(9):818-49, 10/2008. PMID: 18926093.
15. Yendamuri S, Vaporciyan AA, Zaidi T, Feng L, Fernandez R, Bekele NB, Hofstetter WL, Jiang F, Mehran RJ, Rice DC, Spitz MR, Swisher SG, Walsh GL, Roth JA, Katz RL. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol 3(9):979-84, 9/2008. PMID: 18758299.
16. Hu W, Hofstetter W, Guo W, Li H, Pataer A, Peng HH, Guo ZS, Bartlett DL, Lin A, Swisher SG, Fang B. JNK-Deficiency Enhanced Oncolytic Vaccinia Virus Replication and Blocked Activation of Double-Stranded RNA-Dependent Protein Kinase. Cancer Gene Ther, 9/2008. e-Pub 6/2008. PMCID: PMCPMC2553758.
17. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32(9):1404-11, 9/2008. PMID: 18670347.
18. Deus HF, Stanislaus R, Veiga DF, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Chang A, Vogel LH, Almeida JS. A semantic web management model for integrative biomedical informatics. PLoS ONE 3(8):e2946, www.plosone.org, 8/2008. PMCID: PMC2491554.
19. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer, 7/12/2008. PMID: 18623381.
20. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a Tool to Further Subclassify T1b Esophageal Adenocarcinoma. Cancer 112(5):1020-7, 3/1/2008. e-Pub 1/2008. PMID: 18205187.
21. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277-82, 3/2008. PMID: 18317071.
22. Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer 112(3):503-10, 2/1/2008. PMID: 18072264.
23. Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Development of Ad-mda7/IL-24-resistant Lung Cancer Cell Lines. Cancer Biol Ther 7(1):103-108, 1/2008. e-Pub 10/2007. PMID: 18059175.
24. Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK, Swisher SG. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 7(8):2528-2535, 2008. PMID: 18723497.
25. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110(10):2155-68, 11/15/2007. PMID: 17896784.
26. Yendamuri S, Komaki RR, Correa AM, Allen P, Wynn B, Blackmon S, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Mehran RJ. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol 2(11):1022-8, 11/2007. PMID: 17975494.
27. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 31(11):1719-25, 11/2007. PMID: 18059229.
28. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685-92; discussion 1692-3, 11/2007. PMID: 17954086.
29. Abraham SC, Krasinskas AM, Hofstetter WL, Swisher SG, Wu TT. "Seedling" Mesenchymal Tumors (Gastrointestinal stromal tumors and leiomyomas) are Common Incidental Tumors of the Esophagogastric Junction. Am J Surg Pathol 31(11):1629-35, 11/2007. PMID: 18059218.
30. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res 13(20):6032-9, 10/15/2007. PMID: 17947465.
31. Ajani JA, Correa AM, Swisher SG, Wu TT. For localized gastroesophageal cancer, you give chemoradiation before surgery but then what happens? J Clin Oncol 25(27):4315-6, 9/20/2007. PMID: 17878485.
32. Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC. Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis. Ann Thorac Surg 84(3):973-80, 9/2007. PMID: 17720411.
33. Bakaeen F, Rice D, Correa AM, Walsh GL, Vaporciyan AA, Putnam JB, Swisher SG, Roth JA, Huh J, Chu D, Smythe WR. Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg 84(3):982-6, 9/2007. PMID: 17720413.
34. Hu W, Davis JJ, Zhu H, Dong F, Guo W, Ang J, Peng H, Guo ZS, Bartlett DL, Swisher SG, Fang B. Redirecting Adaptive Immunity Against Foreign Antigens to Tumors for Cancer Therapy. Cancer Biol Ther 6(11), 8/12/2007. PMID: 17986853.
35. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed Modification of Nodal Status in AJCC Esophageal Cancer Staging System. Ann Thorac Surg 84(2):365-73; discussion 374-5, 8/2007. PMID: 17643602.
36. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16(6):1200-5, 6/2007. PMID: 17548685.
37. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol 14(4):1305-11, 4/2007. PMID: 17253104.
38. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 25(6):698-707, 2/20/2007. PMID: 17308274.
39. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109(1):125-134, 2007. PMID: 17146785.
40. Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue. Cancer Gene Ther 14:12-18, 2007. PMID: 17024233.
41. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 31(1):58-64, 2007. PMID: 17197919.
42. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109(4):658-667, 2007. PMID: 17211865.
43. Blackmon SH, Correa AM, Wynn B, Hofstetter WL, Martin LW, Mehran RJ, Rice DC, Swisher SG, Walsh GL, Roth JA, Vaporciyan AA. Propensity-Matched Analysis of Three Techniques for Intrathoracic Esophagogastric Anastomosis. Ann Thorac Surg 83(5):1805-1813, 2007. PMID: 17462404.
44. Swisher SG, Hofstetter WL, Miller MJ. The supercharged microvascular jejunal interposition. Semin Thorac Cardiovasc Surg 19(1):56-65, 2007. PMID: 17403459.
45. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103(7):1347-1355, 4/2005. PMID: 15719440.
46. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101(8):1776-1785, 10/2004. PMID: 15386332.
47. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152-1160, 10/2004. PMID: 15464463.
48. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100(11):2347-2354, Sep-Oct, 6/2004. PMID: 15160337.
49. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. PMID: 12538456.
50. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 236(3):376-384; discussion 384-385, 9/2002. PMID: 12192324.
51. Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 277(23):20301-20308, 6/2002. PMID: 11909872.
52. Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem 277(11):9219-9225, 3/2002. PMID: 11741880.
53. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123(1):175-183, 2002. PMID: 11782772.
54. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:279-286, 7/2001. PMID: 11466680.
55. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 119:1126-1132, 6/2000. PMID: 10838528.
56. Kagawa S, Gu J, Swisher SG, Ji L, Roth JA, Lai D, Stephens LC, Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 60:1157-1161, 3/2000. PMID: 10728665.
57. Pearson AS, Spitz FR, Swisher SG, Kataoka M, Sarkiss MG, Meyn RE, McDonnell TJ, Cristiano RJ, Roth JA. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 6:887-890, 3/2000. PMID: 10741712.
58. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18:609-622, 2/2000. PMID: 10653876.
59. Putnam JB, Jr, Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA, Smythe WR, Merriman KW, DeFord LL. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 69:369-375, 2/2000. PMID: 10735665.
60. Gandhi S, Walsh GL, Komaki R, Gokaslan ZL, Nesbitt JC, Putnam JB, Jr, Roth JA, Merriman KW, McCutcheon IE, Munden RF, Swisher SG. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg 68:1778-1784; discussion 1784-1785, 11/1999. PMID: 10585058.
61. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763-771, 5/1999. PMID: 10328106.
62. Gokaslan ZL, York JE, Walsh GL, McCutcheon IE, Lang FF, Putnam JB, Jr, Wildrick DM, Swisher SG, Abi-Said D, Sawaya R. Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg 89:599-609, 10/1998. PMID: 9761054.
63. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25:33-37, 6/1998. PMID: 9704675.
64. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 57:4722-4726, 11/1997. PMID: 9354430.

Grant & Contract Support

Title: Role of Krueppel Like Factor-4 (KLF4) in Lung Cancer
Funding Source: UT SPORE
Role: Principal Investigator
Duration: 3/1/2008 - 2/28/2009
 
Title: Early prediction of pathological response of chemoradiotherapy with FLT PET
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: K.S. Clifford Chao, M.D.
Duration: 9/25/2006 - 7/31/2008
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Roy Herbst

Last updated: 9/11/2009